Nuvation Bio (NUVB) Expected to Announce Quarterly Earnings on Thursday

Nuvation Bio (NYSE:NUVB) is projected to announce its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to post earnings of ($0.1417) per share and revenue of $27.0270 million for the quarter. Individuals may review the information on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:00 AM ET.

Nuvation Bio (NYSE:NUVB) last issued its quarterly earnings data on Monday, May 4th. The company reported $0.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.04. Nuvation Bio had a negative net margin of 102.06% and a negative return on equity of 44.10%. The business had revenue of $83.23 million during the quarter, compared to analyst estimates of $66.22 million. On average, analysts expect Nuvation Bio to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Nuvation Bio Trading Up 4.8%

NUVB opened at $6.46 on Wednesday. Nuvation Bio has a fifty-two week low of $2.18 and a fifty-two week high of $9.75. The company has a debt-to-equity ratio of 0.15, a current ratio of 7.44 and a quick ratio of 7.24. The firm has a market capitalization of $2.25 billion, a price-to-earnings ratio of -15.01 and a beta of 1.52. The company’s 50 day moving average price is $5.66 and its two-hundred day moving average price is $5.23.

Insider Activity

In other news, Director Robert Mashal purchased 25,000 shares of the company’s stock in a transaction dated Tuesday, June 9th. The shares were purchased at an average price of $4.73 per share, for a total transaction of $118,250.00. Following the transaction, the director owned 225,000 shares of the company’s stock, valued at approximately $1,064,250. This trade represents a 12.50% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Stacy Markel sold 125,000 shares of the company’s stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $6.03, for a total transaction of $753,750.00. Following the completion of the sale, the insider directly owned 32,591 shares in the company, valued at approximately $196,523.73. This represents a 79.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 235,668 shares of company stock worth $1,419,495 over the last quarter. Company insiders own 30.11% of the company’s stock.

Institutional Trading of Nuvation Bio

A number of institutional investors have recently bought and sold shares of the company. Rangeley Capital LLC acquired a new stake in Nuvation Bio during the 2nd quarter worth about $25,000. Parallel Advisors LLC lifted its stake in shares of Nuvation Bio by 51.9% in the 3rd quarter. Parallel Advisors LLC now owns 7,597 shares of the company’s stock valued at $28,000 after purchasing an additional 2,597 shares during the period. Cetera Investment Advisers acquired a new position in shares of Nuvation Bio in the 2nd quarter valued at about $29,000. Captrust Financial Advisors bought a new stake in shares of Nuvation Bio during the 2nd quarter valued at about $32,000. Finally, Focus Partners Wealth bought a new stake in shares of Nuvation Bio during the 3rd quarter valued at about $49,000. Institutional investors own 61.67% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. Citigroup reiterated a “market outperform” rating on shares of Nuvation Bio in a report on Wednesday, June 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Nuvation Bio in a report on Friday, July 17th. Zacks Research raised Nuvation Bio from a “strong sell” rating to a “hold” rating in a research report on Monday, July 6th. Wedbush reaffirmed an “outperform” rating and set a $11.00 target price on shares of Nuvation Bio in a report on Thursday, July 23rd. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Nuvation Bio in a report on Wednesday, July 22nd. Eight research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Nuvation Bio has an average rating of “Moderate Buy” and an average target price of $12.88.

About Nuvation Bio

Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.

The company’s pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.